FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).

被引：0
|
作者：
Iravani, Amir
Wallace, Roslyn
Lo, Serigne
Galligan, Anna
Weppler, Alison
Au-Yeung, George
Kee, Damien
Lau, Peter Kar Han
Brady, Benjamin M.
Lee, Belinda
McArthur, Grant A.
Sandhu, Shahneen Kaur
Hicks, Rodney J.
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10041
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SAFETY PROFILE OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) COMBINATION THERAPY IN PATIENTS WITH ADVANCED MELANOMA (MEL)
    Sznol, Mario
    Ferrucci, Pier
    Hogg, David
    Atkins, Michael
    Wolter, Pascal
    Guidoboni, Massimo
    Lebbe, Celeste
    Kirkwood, John
    Schachter, Jacob
    Daniels, Gregory
    Hassel, Jessica
    Cebon, Jonathan
    Gerritsen, Winald
    Atkinson, Victoria
    Thomas, Luc
    Mccaffrey, John
    Power, Derek
    Jiang, Joel
    Hodi, Stephen
    Wolchok, Jedd
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 118 - 118
  • [2] FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab
    Iravani, Amir
    Wallace, Roslyn
    Lo, Serigne N.
    Galligan, Anna
    Weppler, Alison M.
    Hicks, Rodney J.
    Sandhu, Shahneen
    RADIOLOGY, 2023, 307 (03)
  • [3] Characterisation of Complete Responses (CRS) in Patients With Advanced Melanoma (MEL) who Received the Combination of Nivolumab (NIVO) and Ipilimumab (IPI), NIVO, or IPI Alone
    Robert, Caroline
    Larkin, James
    Ascierto, Paolo A.
    Long, Georgina V.
    Hassel, Jessica C.
    Schadendorf, Dirk
    Hodi, F. Stephen
    Lebbe, Celeste
    Grob, Jean-Jacques
    Grossmann, Kenneth
    Wagstaff, John
    Chesney, Jason
    Hogg, David
    Bechter, Oliver
    Marquez-Rodas, Ivan
    Pavlick, Anna C.
    DanaWalker
    Bhore, Rafia
    Postow, Michael A.
    Wolchok, Jedd D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 136 - 137
  • [4] Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
    Robert, C.
    Larkin, J.
    Ascierto, P. A.
    Long, G. V.
    Hassel, J. C.
    Schadendorf, D.
    Hodi, F. S.
    Lebbe, C.
    Grob, J-J.
    Grossmann, K.
    Wagstaff, J.
    Chesney, J.
    Hogg, D.
    Bechter, O.
    Marquez-Rodas, I.
    Pavlick, A. C.
    Walker, D.
    Bhore, R.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064).
    Weber, Jeffrey S.
    Gibney, Geoffrey Thomas
    Sullivan, Ryan J.
    Sosman, Jeffrey Alan
    Slingluff, Craig L.
    Lawrence, Donald P.
    Logan, Theodore F.
    Schuchter, Lynn Mara
    Nair, Suresh
    Buchbinder, Elizabeth Iannotti
    Berghorn, Elmer
    Jiang, Joel
    Horak, Christine E.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
    Sznol, M.
    Ferrucci, P. F.
    Hogg, D.
    Atkins, M.
    Wolter, P.
    Guidoboni, M.
    Lebbe, C.
    Kirkwood, J.
    Schachter, J.
    Daniels, G.
    Hassel, J.
    Cebon, J.
    Gerritsen, W.
    Atkinson, V.
    Thomas, L.
    McCaffrey, J.
    Power, D.
    Jiang, J.
    Hodi, F. S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Prognostic Value of Metabolic Tumor Volume on Pretreatment F-18 FDG PET/CT in Patients with Advanced Melanoma Treated with Ipilimumab
    Ito, Kimiteru
    Teng, Rebecca
    Schoder, Heiko
    Weber, Wolfgang
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [8] ASSESSMENT OF THE IMMUNOGENICITY OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) IN COMBINATION AND POTENTIAL IMPACT ON SAFETY AND EFFICACY IN PATIENTS WITH ADVANCED MELANOMA
    Statkevich, P.
    Passey, C.
    Park, J.
    Saeger, S.
    Bello, A.
    Roy, A.
    Agrawal, S.
    Gupta, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S64 - S64
  • [9] Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma.
    Warner, Allison Betof
    Shoushtari, Alexander Noor
    Houghton, Sean
    Panageas, Katherine
    Chapman, Paul B.
    Wolchok, Jedd D.
    Postow, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
    Pelster, Meredith
    Gruschkus, Stephen K.
    Bassett, Roland
    Gombos, Dan S.
    Shephard, Michael
    Posada, Liberty
    Glover, Maura
    Diab, Adi
    Hwu, Patrick
    Patel, Sapna Pradyuman
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345